Contact
Technology

Harbour Mice® HCAb & H2L2

Harbour Mice®

Industry-leading fully human antibody platforms

Transgenic mice have revolutionized biologic drug discovery by enabling the generation of fully human antibodies. The majority of fully human antibodies approved by the U.S. Food and Drug Administration (FDA) have originated from transgenic mouse platforms.

Nona Biosciences’ biologic drug discovery programs are based on two proprietary transgenic mouse platforms for generating human therapeutic antibodies. These platforms have extensive potential for generating both conventional as well as the next-generation biologics that are fully human, affinity matured with excellent solubility and developability.

Explore HCAb
Explore H2L2

HCAb Harbour Mice®

A unique platform to generate fully human heavy chain only and VHH single domain antibodies

HCAb
  • The world’s first fully human HCAb transgenic mouse platform.
  • The first clinically validated platform to generate fully human HCAb and fully human VHH single domain antibodies.
  • Exceptional versatility for diverse applications using VHH single-domain antibodies as a plug-and-play platform, including bi/multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADC), mRNA technologies, and diagnostic imaging.

HCAb’s patented technology revolutionizes antibody development by generating unique fully human “heavy chain only” antibodies and fully human VHH single domain antibodies that are approximately half the size of a typical IgG. These antibodies possess IgG-like pharmacokinetic (PK) properties and Fc-domain functions, eliminating the need for additional engineering or humanization. Lack of light chains avoids the problem of light chain mispairing and heterodimerization. These distinctive attributes empower the creation of products with exceptional characteristics not attainable through conventional antibody platforms.

H2L2 Harbour Mice®

Transgenic mice bearing fully human immunoglobulin genes with robust B cell development and antibody maturation

H2L2
  • Robust and highly efficent
  • Global IP
  • Clinically validated

Both of these platforms hold immense potential in generating therapeutic antibodies and expediting the process of drug discovery and development. Their unique capabilities pave the way for the creation of novel therapeutics and enable researchers to explore new avenues in biologics research. These platforms offer exciting opportunities for advancing the field of biologics and will ultimately improve outcomes for patients.

HCAb Harbour Mice®

A unique platform to generate fully human heavy chain only antibodies

HCAb
  • The world’s first fully human HCAb transgenic mouse platform.
  • The first clinically validated fully human HCAb platform.
  • Remarkable versatility for broad applications. Bi- and multi-specific antibodies, CAR-T, ADC, mRNA and diagnostic imaging

HCAb’s patented technology revolutionizes antibody development by generating unique fully human “heavy chain only” antibodies that are approximately half the size of a typical IgG. These antibodies possess IgG-like pharmacokinetic (PK) properties and Fc-domain functions, eliminating the need for additional engineering or humanization. Lack of light chains avoids the problem of light chain mispairing and heterodimerization. These distinctive attributes empower the creation of products with exceptional characteristics not attainable through conventional antibody platforms.

H2L2 Harbour Mice®

Transgenic mice bearing fully human immunoglobulin genes with robust B Cell development & Antibody maturation

H2L2
  • Robust and highly efficent
  • Global IP
  • Clinically validated

Both of these platforms hold immense potential in generating therapeutic antibodies and expediting the process of drug discovery and development. Their unique capabilities pave the way for the creation of novel therapeutics and enable researchers to explore new avenues in biologics research. These platforms offer exciting opportunities for advancing the field of biologics and will ultimately improve outcomes for patients.

Transform your biotech future

Ready to pioneer the next wave of biotech innovation? Contact us today and let’s embark on a journey to transform your ideas into reality.

Contact Us
Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from - Youtube
Vimeo
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Spotify
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound
Contact